JP Morgan Maintains Neutral on Johnson & Johnson, Raises Price Target to $300
JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $285 to $300.
Last updated: 2026-11-21 20:31:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Johnson & Johnson (JNJ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $270.77, with a market capitalization of $643.09B and a P/E ratio of 39.96. Over the past 52 weeks, its price has ranged from $199.91 to $290.25. This page covers its latest market performance, valuation, price trends and company information.
$643.09B | |
$270.36 | |
$272.46 | |
$268.00 | |
$267.14 | |
8.08M | |
7.33M | |
39.96 | |
$290.25 | |
$199.91 | |
1.98% | |
2026-09-27 |
Johnson & Johnson (JNJ) last closed at $270.77 as of 2026-11-21 00:59:49, up 1.25% ($3.33) from the previous close of $267.14.
During the latest regular trading session, JNJ traded between $268.00 and $272.46, with a volume of 8.08M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Johnson & Johnson (JNJ) moved from $283.52 to $270.77, representing a decline of 4.50% ($12.75).
The stock traded between $264.68 and $290.25 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 8.84 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 78.4%
JNJ is currently trading at $270.77, placing it 78.4% of the way from its 52-week low of $199.91 to its 52-week high of $290.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 140,800 |
| CEO | Joaquin Duato |
| Founded | 1886 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Johnson & Johnson.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 24, 2026 |
| Payment Date | Dec 8, 2026 |
| Dividend Per Share | $1.34 |
Latest news related to Johnson & Johnson and JNJ stock.
JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $285 to $300.
Six sectors are higher and five are lower in Friday's regular session, with defensive sectors holding two of the top three positions alongside Energy. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 studyTREMFYA
Johnson & Johnson announced Week-24 results from the Phase 4 STAR study showing TREMFYA (guselkumab) met primary and secondary endpoints in treating psoriatic arthritis with axial involvement. The IL-23 inhibitor demonstrated statistically significant improvements in disease activity (BASDAI scores) and more than 2 times greater reduction in MRI-assessed sacroiliac joint inflammation compared to placebo, with a consistent safety profile.
Johnson & Johnson's $3.05 billion acquisition of Halda Therapeutics is showing promise as JNJ-6143 demonstrated excellent results in early-stage prostate cancer trials, with a 75% overall response rate in heavily pre-treated patients. The company's strong pipeline, recent drug launches, and status as a Dividend King with 64 consecutive years of dividend increases make it attractive for long-term investors.
Eligible investors can buy real shares of Johnson & Johnson (JNJ) through MEXC Stocks. Follow these three steps to open a Stocks account, transfer USDT, and place a Stocks order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to JNJ, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between JNJ shares and USD.
JNJ Shares to USD
1.00 JNJ shares = 270.774 USD
Calculations are estimates based on the latest available price and are for reference only.